PTC Therapeutics Reports Strong 2025 Revenue Growth on Sephience Launch
Event summary
- PTC Therapeutics reported full-year 2025 product and royalty revenue of $831M, exceeding guidance.
- Sephience generated $111M in net revenue since its launch in the second half of 2025.
- The company sold remaining Evrysdi royalties to Royalty Pharma for $240M upfront plus potential milestones.
- PTC expects Sephience global footprint to expand to 20-30 countries by end of 2026.
The big picture
PTC Therapeutics' strong financial performance in 2025 was driven by the successful launch of Sephience and strategic royalty sales. The company is positioning itself for continued growth through its diversified pipeline and robust commercial infrastructure, while navigating regulatory pathways for key programs. With a solid cash position and expanding global footprint, PTC appears well-positioned to capitalize on opportunities in the rare disease market.
What we're watching
- Commercial Execution
- Whether PTC can sustain Sephience's strong uptake and expand its global footprint as projected.
- Regulatory Pathways
- The FDA's openness to accelerated approval for votoplam in Huntington's disease and the requirements for vatiquinone resubmission.
- Financial Strategy
- How PTC will allocate its $1.95B cash position as it approaches cash flow breakeven.